Devyser Diagnostics AB (publ) (DVYSR.ST)

SEK 117.0

(0.0%)

Total Liabilities Summary of Devyser Diagnostics AB (publ)

  • Devyser Diagnostics AB (publ)'s latest annual total liabilities in 2023 was 125 Million SEK , up 80.66% from previous year.
  • Devyser Diagnostics AB (publ)'s latest quarterly total liabilities in 2024 Q2 was 121.9 Million SEK , down -0.97% from previous quarter.
  • Devyser Diagnostics AB (publ) reported annual total liabilities of 69.19 Million SEK in 2022, up 72.19% from previous year.
  • Devyser Diagnostics AB (publ) reported annual total liabilities of 40.18 Million SEK in 2021, down -7.8% from previous year.
  • Devyser Diagnostics AB (publ) reported quarterly total liabilities of 121.9 Million SEK for 2024 Q2, down -0.97% from previous quarter.
  • Devyser Diagnostics AB (publ) reported quarterly total liabilities of 123.1 Million SEK for 2024 Q1, down -1.52% from previous quarter.

Annual Total Liabilities Chart of Devyser Diagnostics AB (publ) (2023 - 2018)

Historical Annual Total Liabilities of Devyser Diagnostics AB (publ) (2023 - 2018)

Year Total Liabilities Total Liabilities Growth
2023 125 Million SEK 80.66%
2022 69.19 Million SEK 72.19%
2021 40.18 Million SEK -7.8%
2020 43.58 Million SEK 18.78%
2019 36.69 Million SEK 101.02%
2018 18.25 Million SEK 0.0%

Peer Total Liabilities Comparison of Devyser Diagnostics AB (publ)

Name Total Liabilities Total Liabilities Difference
AroCell AB (publ) 11.24 Million SEK -1011.506%
Immunovia AB (publ) 31.69 Million SEK -294.446%
Prostatype Genomics AB (publ) 24.54 Million SEK -409.206%
SenzaGen AB 29.56 Million SEK -322.754%
Spermosens AB 13.41 Million SEK -831.932%